---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-22-000215"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:59:34.697318+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q1 net sales up 15% to $6.2M, net loss widens to $2.5M, raises FY22 revenue guidance

## Summary
- Net sales $6.24M (+15% YoY); domestic core up 13.2%, novel therapies $0.36M (including NRE).
- GAAP net loss $2.5M (-$0.06 EPS) vs $1.3M loss (-$0.03 EPS) prior year; adjusted EPS -$0.05.
- Gross margin 58.0% (-150bps) on higher raw material/labor costs; operating expenses $6.7M (+24% YoY).
- Raises FY22 revenue guidance to $26.5-$27.0M (prev $26.0-$27.0M); reaffirms 60% gross margin exit run rate.

## SEC filing metadata
- accession: 0001161697-22-000215
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169722000215/0001161697-22-000215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169722000215/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-22-000215
- JSON: https://secwatch.observer/filing/0001161697-22-000215.json
- Plain text: https://secwatch.observer/filing/0001161697-22-000215.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.